Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

577 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
Diamond B, Ziccheddu B, Maclachlan K, Taylor J, Boyle E, Ossa JA, Jahn J, Affer M, Totiger TM, Coffey D, Chandhok N, Watts J, Cimmino L, Lu SX, Bolli N, Bolton K, Landau H, Park JH, Ganesh K, McPherson A, Sekeres MA, Lesokhin A, Chung DJ, Zhang Y, Ho C, Roshal M, Tyner J, Nimer S, Papaemmanuil E, Usmani S, Morgan G, Landgren O, Maura F. Diamond B, et al. Among authors: usmani s. Blood. 2023 May 11;141(19):2359-2371. doi: 10.1182/blood.2022018244. Blood. 2023. PMID: 36626250 Free PMC article.
Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations.
Maclachlan KH, Bagratuni T, Kastritis E, Ziccheddu B, Lu S, Yellapantula V, Famulare C, Argyropoulos K, Derkach A, Papaemmanuil E, Dogan A, Lesokhin A, Usmani SZ, Landgren CO, Palomba LM, Maura F, Dimopoulos MA. Maclachlan KH, et al. Among authors: usmani sz. Blood Adv. 2023 Mar 28;7(6):971-981. doi: 10.1182/bloodadvances.2022008876. Blood Adv. 2023. PMID: 36332058 Free PMC article.
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach.
Pianko MJ, Tiutan T, Derkach A, Flynn J, Salvatore SP, Jaffer-Sathick I, Rossi AC, Lahoud O, Hultcrantz M, Shah UA, Maclachlan K, Chung DJ, Shah GL, Landau HJ, Korde N, Mailankody S, Lesokhin AM, Tan C, Scordo M, Jaimes EA, Giralt SA, Usmani S, Hassoun H. Pianko MJ, et al. Among authors: usmani s. Am J Hematol. 2023 Mar;98(3):421-431. doi: 10.1002/ajh.26801. Epub 2023 Jan 1. Am J Hematol. 2023. PMID: 36588413 Free PMC article.
Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study.
Korde N, Tavitian E, Mastey D, Lengfellner J, Hevroni G, Zarski A, Salcedo M, Mailankody S, Hassoun H, Smith EL, Hultcrantz M, Shah U, Tan C, Diamond B, Shah G, Scordo M, Lahoud O, Chung DJ, Landau H, Giralt S, Derkach A, Atkinson TM, Sabbatini P, König F, Usmani SZ, Landgren O, Lesokhin AM. Korde N, et al. Among authors: usmani sz. EClinicalMedicine. 2023 Feb 27;57:101854. doi: 10.1016/j.eclinm.2023.101854. eCollection 2023 Mar. EClinicalMedicine. 2023. PMID: 36895800 Free PMC article.
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Cirrincione AM, Poos AM, Ziccheddu B, Kaddoura M, Baertsch MA, Maclachlan KH, Chojnacka M, Diamond BT, John L, Reichert P, Huhn S, Blaney P, Gagler DC, Rippe K, Zhang Y, Dogan A, Lesokhin AM, Davies FE, Goldschmidt H, Fenk R, Weisel KC, Mai EK, Korde N, Morgan GJ, Usmani SZ, Landgren O, Raab MS, Weinhold N, Maura F. Cirrincione AM, et al. Among authors: usmani sz. Blood. 2024 May 10:blood.2024024299. doi: 10.1182/blood.2024024299. Online ahead of print. Blood. 2024. PMID: 38728430
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
Firestone RS, Socci ND, Shekarkhand T, Zhu M, Ge Qin W, Hultcrantz ML, Mailankody S, Tan CR, Korde N, Lesokhin AM, Hassoun H, Shah UA, Maclachlan KH, Rajeeve S, Landau HJ, Scordo M, Shah GL, Lahoud OB, Giralt SA, Murata K, Usmani SZ, Chung DJ. Firestone RS, et al. Among authors: usmani sz. Blood. 2024 May 10:blood.2023023557. doi: 10.1182/blood.2023023557. Online ahead of print. Blood. 2024. PMID: 38728378
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk NWCJ, Leleu X, Pérez-Larraya JG, Manier S, Nooka AK, Mateos MV, Einsele H, Minnema M, Cavo M, Derman BA, Puig N, Gay F, Ho PJ, Chng WJ, Kastritis E, Gahrton G, Weisel K, Nagarajan C, Schjesvold F, Mikhael J, Costa L, Raje NS, Zamagni E, Hájek R, Weinhold N, Yong K, Ye JC, Sidhana S, Merlini G, Martin T, Lin Y, Chari A, Popat R, Kaufman JL; International Myeloma Working Group. Rodriguez-Otero P, et al. Among authors: usmani s. Lancet Oncol. 2024 May;25(5):e205-e216. doi: 10.1016/S1470-2045(24)00043-3. Lancet Oncol. 2024. PMID: 38697166 Review.
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1.
Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R, Lau OS, Nielsen K, Davis C, Patel JH, Banerjee A, Stephenson T, Uhlar C, Kobos R, Goldberg JD, Pei L, Trancucci D, Girgis S, Wang Lin SX, Wu LS, Moreau P, Usmani SZ, Bahlis NJ, van de Donk NWCJ, Verona R. Cortes-Selva D, et al. Among authors: usmani sz. Blood. 2024 Apr 24:blood.2023022823. doi: 10.1182/blood.2023022823. Online ahead of print. Blood. 2024. PMID: 38657201
577 results